Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection

Annals of Pharmacotherapy

Volumn 41, Issue 12, 2007, Pages 1992-2001

  Segarra Newnham, Marisel ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Albendazole; Hyperinfection; Ivermectin; Strongyloides stercoralis; Thiabendazole

Indexed keywords

ALBENDAZOLE; ANTHELMINTIC AGENT; CORTICOSTEROID; IVERMECTIN; TIABENDAZOLE;

ABDOMINAL PAIN; ARTICLE; CLINICAL FEATURE; DIARRHEA; DIZZINESS; FECES CULTURE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER TOXICITY; MULTIPLE CYCLE TREATMENT; PARASITE CULTIVATION; PRIORITY JOURNAL; PRURITUS; SHOE; SOIL POLLUTION; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; SUPERINFECTION;

ALBENDAZOLE; ANIMALS; ANTINEMATODAL AGENTS; HUMANS; IVERMECTIN; RISK FACTORS; STRONGYLOIDES STERCORALIS; STRONGYLOIDIASIS; THIABENDAZOLE;

EID: 36849094328     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K302     Document Type: Article

References (72)

1. Linder JD, Monkemuller KE, Lazenby AJ, Wilcox CM. Streptococcus bovis bacteremia associated with Strongyloides stercoralis colitis. Gastrointest Endosc 2000;52:796-8.
2. El-Dib NA. Strongyloidiasis. In: Kamel R, Lumley J, eds. Textbook of tropical surgery. London: Westminster Publishing Ltd., 2004:1035-7.
3. Maguire JH. Intestinal nematodes (roundworms). In: Mandell GI, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingston. 2005:3260-7.
4. Boulware DR, Stauffer WM, Hendel-Paterson BR, et al. Maltreatment of Strongyloides infection: case series and worldwide physicians-in-training survey. Am J Med 2007;120:545-51.
5. Igra-Siegman Y, Kapila R, Sen P, Kaminski C, Louria DB. Syndrome of hyperinfection with Strongyloides stercoralis. Rev Infect Dis 1981;3:397-407.
6. Adedayo O, Grell G, Bellot P. Hyperinfective strongyloidiasis in the medical ward: a review of 27 cases in 5 years. South Med J 2002;95:711-6.
7. Satoh M, Kokaze A. Treatment strategies in controlling strongyloidiasis. Expert Opin Pharmacother 2004;5:2293-301. DOI 10.1517/14656566.5.11,2293
8. Zaha O, Hirata T, Kinjo F, Saito A. Strongyloidiasis - progress in diagnosis and treatment. Intern Med 2000;39:695-700.
9. Centers for Disease Control and Prevention. Strongyloidiasis, www.dpd. cdc.gov/dpdx/HTML/Strongyloidiasis.htm (accessed 2007 Aug 17).
10. Concha R, Harrington W, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcomes. J Clin Gastroenterol 2005;39:203-11.
11. Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis 2001;33:1040-7.
12. DeVault GA, King JW, Rohr MS, Landreneau MD, Brown ST, McDonald JC. Opportunistic infections with Strongyloides stercoralis in renal transplant. Rev Infect Dis 1990;12:653-71.
13. Hsieh YP, Won YK, Chen ML. Minimal change nephrotic syndrome in association with strongyloidiasis. Clin Nephrol 2006;66:459-63.
14. Safdar A, Malathum K, Rodriguez SJ, Husni R, Rolston KVI. Strongyloidiasis in patients at a comprehensive cancer center in the United States: a retrospective study covering the years 1971-2003. Cancer 2004;100:1531-6. DOI 10.1002/cncr.20120
15. Lim S, Katz K, Krajden S, Fuksa M, Keystone JS, Kain KC. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 2004;171:479-84. DOI 10.1503/cmaj.1031698
16. Gupta S, Jain A, Fanning TV, Couriel DR, Jimenez CA, Eapen GA. An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: a case report. BMC Cancer 2006;6:87. DOI 10.1186/1471-2407-6-87
17. Gotuzzo E, Terashima A, Alvarez H, et al. Strongyloides stercoralis hyperinfection associated with human T cell lymphotropic virus type-1 infection in Peru. Am J Trop Med Hyg 1999;60:146-9.
18. Ohnishi K, Kogure H, Kaneko S, Kato Y, Akao N. Strongyloidiasis in a patient with acquired immunodeficiency syndrome. J Infect Chemother 2004;10:178-80.
19. Keiser PB, Nutman TB. Strongyloides stercoralis in the immunocompromised population. Clin Microbiol Rev 2004;17:208-17. DOI 10.1128/CMR.17.1.208-217.2004
20. Seet RCS, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol 2005;12:680-2. DOI 10.1128/CDLI.12.5.680-682.2005
21. Hauber HP, Galle J, Chiodini PL, et al. Fatal outcome of a hyperinfection syndrome despite successful eradication of Strongyloides with subcutaneous ivermectin. Infection 2005;33:383-6. DOI 10.1007/s15010-005-5060-x
22. Link K, Orenstein R. Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis. South Med J 1999;92:728-31.
23. Ashraf M, Gue CL, Baddour LM. Strongyloidiasis refractory to treatment with ivermectin. Am J Med Sci 1996;311:178-9.
24. Newberry AM, Williams DN, Stauffer WM, Boulware DR. Hendel-Paterson BR, Walker PF. Strongyloides hyperinfection presented as acute respiratory failure and Gram-negative sepsis. Chest 2005;128:3681-4.
25. Wong TYH, Szeto CC, Lai FFM, Mak CK, Li PKT. Nephrotic syndrome in strongyloidiasis: remission after eradication with antihelminthic agents. Nephron 1998;79:333-6.
26. Namisato S, Motomura K, Haranga S, et al. Pulmonary strongyloidiasis in a patient receiving prednisolone therapy. Intern Med 2004;43:731-6.
27. Sylesh A, Rajan R, Subhalal N, Subhalal S, Subhalal L, Priyadarsini R. Paralytic ileus due to strongyloidosis (letter). Indian J Gastroenterol 2005;24:228.
28. de Silva T, Raychaudhuri M, Poulton M. HIV infection associated with Strongyloides stercoralis colitis resulting in Streptococcus bovis bacteraemia and meningitis. Sex Transm Infect 2005;81:276-7. DOI 10.1136/sti.2004.01239
29. Pacanowski J, Dos Santos M, Roux A, et al. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report. Am J Trop Med Hyg 2005;73:122-4.
30. Hoey WE, Roberts NJ, Bryson MF, et al. Transmission of strongyloidiasis by kidney transplant? Disseminated strongyloidiasis in both recipients of kidney allografts from a single cadaver donor. JAMA 1981;246:1937-9.
31. Lam CS, Tong MKH, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006;25:14-8. DOI 10.1007/s10096-005-0070-2
32. Csermely L, Jaafar H, Kristensen J, et al. Strongyloides hyper-infection causing life-threatening gastrointestinal bleeding. World J Gastroenterol 2006;12:6401-4.
33. Hirata T, Uchima N, Kishimoto K, et al. Impairment of host immune response against Strongyloides stercoralis by human T cell lymphotropic virus type 1 infection. Am J Trop Med Hyg 2006;74:246-9.
34. Liu LX, Weller PF. Strongyloidiasis and other intestinal nematode infections. Infect Dis Clin N Am 1993;7:655-82.
35. Lanzafame M, Faggian F, Lattuada E, Antolini D, Vento S. Strongyloidiasis in an HIV-1-infected patient after highly active antiretroviral therapy-induced immune restoration (letter). J Infect Dis 2005;191:1027.
36. Orem J, Mayanja B, Okongo M, Morgan D. Strongyloides stercoralis hyperinfection in a patient with AIDS in Uganda successfully treated with ivermectin (letter). Clin Infect Dis 2003;37:152-3.
37. Satyanarayana S, Nema S, Kalghatgi AT, et al. Disseminated Strongyloides stercoralis in AIDS: a report from India. Indian J Pathol Microbiol 2005;48:472-4.
38. Kim AC, Lupatkin HC. Strongyloides stercoralis infection as a manifestation of immune restoration syndrome (letter). Clin Infect Dis 2004;39:439-40.
39. Brown M, Cartledge JD, Miller RF. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS 2006;17:560-1.
40. Viney ME, Brown M, Omoding NE, et al. Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis 2004;190:2175-80.
41. Taylor CL, Subbarao V, Gayed S, Ustianowski AP. Immune reconstitution syndrome to Strongyloides stercoralis infection (letter). AIDS 2007;21:649-50.
42. Shelburne SA, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003;5:67-79.
43. Currie BJ, McCarthy JS. Strongyloides stercoralis infection as a manifestation of immune restoration syndrome (letter). Clin Infect Dis 2005;40:635.
44. Czachor JS, Jonas AP. Transmission of Strongyloides steracolis person to person. J Travel Med 2000;7:211-2.
45. Chiodini PL, Reid AJC, Wiselka MJ, Firmin R, Foweraker J. Parenteral ivermectin in Strongyloides hyperinfection (letter). Lancet 2000;355:43-4.
46. Hughes R, McGuire G. Delayed diagnosis of disseminated strongyloidiasis. Intensive Care Med 2001;27:310-2. DOI 10.1007/s001340000798
47. Steiner B, Riebold D, Wolff D, Freund M, Reisinger EC. Strongyloides stercoralis eggs in a urethral smear after bone marrow transplantation (letter). Clin Infect Dis 2002;34:1280-1.
48. Lemos LB, Qu Z, Laucirica R, Fred HL. Hyperinfection syndrome in strongyloidiasis: report of two cases. Ann Diagn Path 2003;7:87-94. DOI 10.1053/adpa.2003.50019
49. Potter A, Stephens D, De Keulenaer B. Strongyloides hyper-infection: a case for awareness. Ann Trop Med Parasitol 2003;97:855-60. DOI 10.1179/000349803225002453
50. Gulbas Z, Kebapci M, Pasaoglu O, Vardereli E. Successful ivermectin treatment of hepatic strongyloidiasis presenting with severe eosinophilia. South Med J 2004;97:907-10.
51. Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Pub Health 2004;35:531-4.
52. Abdalla J, Saad M, Myers JW, Moorman JP. An elderly man with immunosuppression, shortness of breath, and eosinophilia. Clin Infect Dis 2005;40:1464, 1535-6.
53. Arsić-Arsenijević V, Dzamić A, Dzamić Z, Milobratović D, Tomić D. Fatal Strongyloides sterocoralis infection in a young woman with lupus glomerulonephritis. J Nephrol 2005;18:787-90.
54. Marty FM, Lowry CM, Rodriguez M, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis 2005;41:e5-e8.
55. Reddy IS, Swarnalata G. Fatal disseminated strongyloidiasis in patients on immunosuppressive therapy. Indian J Dermatol Venerol Leprol 2005;71:38-40.
56. Turner SA, Maclean JD, Fleckenstein L, Greenaway C. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg 2005;73:911-4.
57. Giavina-Bianchi P, Silva Fde S, Toledo-Barros M, Birolini D, Kalil J, Rizzo LV. A rare intestinal manifestation in a patient with common variable immunodeficiency and strongyloidiasis. Int Arch Allergy Immunol 2006;140:199-204. DOI 10.1159/000093205
58. Mora CS, Segami MI, Hidalgo JA. Strongyloides stercoralis hyperinfection in systemic lupus erythematosus and the antiphospholipid syndrome. Semin Arthritis Rheum 2006;36:135-45. DOI 10.1016/j.semarthrit.2006. 06.001
59. Ghoshal UC, Alexender G, Ghoshal U, Tripathi S, Krishnani N. Strongyloides stercoralis infestation in a patient with severe ulcerative colitis. Indian J Med Sci 2006;60:106-10.
60. Loutfy MR, Wilson M, Keystone JS, Kain KC. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 2002;66:749-52.
61. Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994;169:1076-9.
62. Drug topics red book. Montvale, NJ: Thomson Healthcare, Inc., 2007.
63. Package insert. Stromectol (ivermectin). Whitehouse Station. NJ: Merck & Co., September 2005.
64. Pearson RD. Agents active against parasites and Pneumocystis. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingston, 2005:568-603.
65. Toma H, Sato Y, Shiroma Y, Kobayashi J, Shimabukuro I, Takara M. Comparative studies on the efficacy of three antihelminthics on treatment of human strongyloidiasis in Okinawa, Japan. Southeast Asian J Trop Med Public Health 2000;31:147-51.
66. Igual-Adeli R, Oltra-Alcaraz C, Soler-Company E, et al. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004;5:2615-9.
67. Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Derm 2005;44:981-8.
68. Heaton J, Shippey S, Macri C, Macedonia C. Intestinal helminthes infestation in pregnancy: a case report and literature review. Mil Med 2002;167:954-5.
69. Centers for Disease Control and Prevention, Infectious Diseases Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000;49(RR-10):1-125, CE1-7. Erratum: MMWR 2004;53:396.
70. Muennig P, Pallin D, Challah C, Khan K. The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States. Epidemiol Infect 2004;132:1055-63.
71. Seybolt LM, Christiansen D, Barnett ED. Diagnostic evaluation of newly arrived asymptomatic refugees with eosinophilia. Clin Infect Dis 2006;42:363-7.
72. Nutman TB. Asymptomatic peripheral blood eosinophilia redux: common parasitic infections presenting frequently in refugees and immigrants (editorial). Clin Infect Dis 2006;42:368-9.